<DOC>
	<DOC>NCT01106118</DOC>
	<brief_summary>The primary goal of this international non-interventional study is to investigate the therapeutic effectiveness of vardenafil (film-coated tablet) in Erectile Dysfunction patients with the Metabolic Syndrome in daily clinical practice. It will include a large number of patients with various underlying conditions with different cultural and demographic backgrounds from different geographic areas.</brief_summary>
	<brief_title>Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Erectile Dysfunction (ED) patient who has newly been prescribed vardenafil (Levitra filmcoated tablet) in accordance with the terms of the local marketing authorization. Diagnosis of erectile dysfunction at the discretion of the physician, based on the patients ED history. No use of any Phosphodiesterase Type 5 (PDE5) inhibitor within 1 month of study entry. Documented Metabolic Syndrome (MetS), preferably according to the definition of the International Diabetes Foundation. Do not follow the contraindications and warnings of the Summary of Product Characteristics.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>